Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06759636 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Study acronym: FRIENDS-01
StatusRecruiting
PhasePhase 3
Started2025-02-24
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 14, 2026 (before its estimated April 21, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-04-09
Not Yet Recruiting→Recruiting Study Identification, Study Status, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-01-21→confirmed 2025-02-24
Eligibility criteria+343 characters
[...] therapy, immunology, and targeting； 4.ECOG PS score: 0-2； 5.CTITDeveloped patientstreatment-induced needthrombocytopenia twowith platelet testscount between 10×10⁹/L and 75×10⁹/L; if platelet count is between 10×10⁹/L and 50×10⁹/L, one platelet test is required with a 24-hour interval; if platelet count is between 50×10⁹/L and 75×10⁹/L, two platelet tests shouldare be performed 24 hours apart, and the platelet value should be between 10×10^9/L - 75×10^9/Lrequired.； 6.Estimated survival time during screening is ≥ 12 weeks, [...] ≥ 1.5ULN or eGFR ≤ 60 ml/min (Cockcroft Gault formula); 13.Within the f [...] [...]
Study sitesdetails revised at 1 of 1 site
Study title-56 characters
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety W [...]
2024-12-29
Original filing
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Trial Details
NCT Number NCT06759636
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions CTIT: Cancer Therapy Induced Thrombocytopenia
Enrollment 88 participants
Start Date 2025-02-24
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-14